Abstract Library

#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia

Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bottiglieri F, Modica R, de Cicco F, Minotta R, Faggiano A,

Keywords: gastric, neuroendocrine, type1, type3, metastases,

#2809 Sporadic Neuroendocrine Neoplasms in Young Adult Patients: Natural History, Prognosis and Management

Introduction: Data specific to sporadic neuroendocrine neoplasms (NEN) in young adult patients (pts) are limited due to its rare occurrence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Altieri B

Authors: Altieri B, Modica R, Bottiglieri F, de Cicco F, Faggiano A,

Keywords: neuroendocrine neoplasms, young patients, age, natural history, treatment, prognosis,

#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study

Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Massironi S

Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,

Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),

#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study

Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,

Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,